Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.46 |
| ▸ | NPY1R | P25929 | 9/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.46 |
| ▸ | NPY2R | P49146 | 5/20 | 0.46 |
| ▸ | GNPAT | O15228 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 3/20 | 0.42 |
| ▸ | FNTB | P49356 | 3/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.42 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30264773 | 0.94 | APLNR (0.47) | NPY4RNPY1RNPY5RNPY2RAPLNR | |
| SCHEMBL31267994 | 0.94 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RAPLNR | |
| SCHEMBL29420164 | 0.91 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2RGNPAT | |
| SCHEMBL30152128 | 0.91 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2RGNPAT | |
| SCHEMBL30475874 | 0.91 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RGHSR | |
| SCHEMBL29958548 | 0.91 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RGNPAT | |
| SCHEMBL29482503 | 0.90 | FNTA (0.51) | NPY4RNPY1RNPY5RNPY2RGNPAT | |
| SCHEMBL29482469 | 0.90 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RGNPAT | |
| SCHEMBL29511195 | 0.90 | FNTA (0.51) | NPY4RNPY1RNPY5RNPY2RGNPAT | |
| SCHEMBL30475873 | 0.90 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RGNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287154-A1 | MC3R AGONIST PEPTIDES | COURAGE THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287154-A1 | MC3R AGONIST PEPTIDES | MC3R, MC4R, MC1R | NPY4R 15/4885NPY1R 19/4885NPY5R 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.